The molecular adsorbent recirculating system as a liver support system. Summary of Mexican experience
Journal Title: Annals of Hepatology - Year 2014, Vol 13, Issue 2
Abstract
Aim. The aim of this study was to assess the effects of the molecular absorbent recirculating system (MARS) on patients with acute liver failure (ALF) and liver failure with cirrhosis (AoCLF) as well as in cholestatic patients with intractable pruritus in a Mexican population. Material and methods. From August 2003 to December 2011, MARS was used in 38 patients with ALF, 15 patients with AoCLF, and 17 cholestatic patients with intractable pruritus. The patients were examined using a standard liver function test and for vital signs, presence of ascites and encephalopathy before and after each treatment. The therapeutic response, patient status, follow-up status, and need for liver transplantation were determined. Results. Seventy-nine MARS procedures were performed. MARS was used for ALF in 54.3% of patients, AoCLF in 24.2%, and cholestatic disease in 21.5%. There were significant improvements in serum bilirubin (p = 0.000), aspartate aminotransferase (p = 0.000), alanine aminotransferase (p = 0.030), gamma-glytamyl transpeptidase (p = 0.044), alkaline phosphatase (p = 0.006), and encephalopathy grade (p = 0.000). Thirty-eight ALF patients were listed for emergency liver transplantation and treated with MARS; 20 of these patients died on a waiting list, 18 survived. only four underwent liver transplantation and 14 (37%) recovered without transplantation after the MARS procedure. Conclusion. MARS is a safe and effective procedure, especially for ALF patients. Our results suggest that MARS therapy can contribute to native liver recovery in ALF patients.
Authors and Affiliations
Laura Cisneros-Garza, Ma. del Rosario Muñoz-Ramírez, Linda Muñoz-Espinoza, José Ruiz Velasco, Rosalba Moreno-Alcántar, Eduardo Marín-López, Nahum Méndez-Sánchez
Keywords
Related Articles
- EP ID EP78380
- DOI -
- Views 116
- Downloads 0
On the cusp of change: New therapeutic modalities for HCV
We are at the cusp of significant new alternatives for the treatment of chronic hepatitis C. Among more than 100 drugs in development, some are ready to be approved and in the market as soon as next year. The protease in...
Epidemiology of HCV infection in Latin America
Hepatitis C virus is one of the most common causes of chronic liver disease and one of the principal indications for liver transplantation. The prevalence and incidence worldwide is variable, although there may be some s...
Dislodgement of variceal bands after esophageal balloon tamponade for variceal bleeding
A 43-year-old male with alcoholic cirrhosis underwent EGD for hematemesis which revealed bleeding, grade II, lower esophageal varices that were endoscopically ligated with 6 bands. All the bands remained attached to vari...
Portal hypertension and acute liver failure as uncommon manifestations of primary amyloidosis
Hepatic involvement in primary amyloidosis is an infrequent challenge to the hepatologist. Although usually asymptomatic, amyloidosis may have unusual manifestations. Liver biopsy is an important diagnostic tool for this...
The CT Quadrate lobe hot spot sign
Intense enhancement of the quadrate lobe in the arterial phase may be seen on computed tomography in patients of superior vena cava syndrome. We present this imaging finding in a case of lymphoma causing superior vena ca...